Yeni Peptid Antibiyotik Olan Magainin Ve Peksigananın Etkileri

Öz

Kemoterapinin temellerinin atılmış olduğu 20. yüzyılın ortalarında, penisilinin keşfi ile birçok hastalığın tedavisi mümkün olmuş ve bu olay yüzyılın buluşu olarak tarihe geçmiştir. Bundan sonraki yıllar içinde antibiyotiklere karşı gelişen direncin giderek artması yeni antibiyotiklerin geliştirilmesini hızlandırmıştır. Bu araştırmalar sonucunda, son yıllarda antimikrobik peptidler adı verilen yeni bir antibiyotik sınıfı ortaya çıkmıştır

Effects Of Magainin And Pexiganan As New Peptide Antibiotics

Abstract

References

1. Hancock R.E.W, Falla T, Brown M.H. Cationic bactericidal peptides. Adv. Microb. Phsiol 1995; 37: 135-75
2. Kleinkauf H, Dohren H von. Peptide antibiotics beta-lactams and related compounds. Crit. Rev. Biotechnol 1988; : 1-32
3. Perlman D, Bodansky M, Biosynthesis of peptide antibiotics. Annu. Rev. Biochem 1971; 40: 449-64
4. Hancock R.E.W, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 6: 1317-23
5. Csordas A, Michl H. İsolation and structure of a haemolytic polşypeptide from the defensive secretion of European Bombina species. Monatsh. Chem. 1970; 101: 182-9
6. Mor A, Nikolas P. İsolation and structure of novel defensive peptides from frog skin. Eur. J. Biochem. 1994; 219: 54
7. Hancock REW. Peptide antibiotics. Lancet. 1997; 349: 418-22
8. Matsuzaki K. Magainins as paradigm for the mode of action of pore forming polypeptides. Biochim Biophys Acta. ; 1376(3): 391-400

9. Zasloff M, Miyajima K. Mechanism of synergism between antimicrobial peptides magainin 2 and PGLa. Biochemistry, 1998; 37(43): 15144-53
10. Lipsky BA, MacDonald D, Litka PA. Treatment of infected diabetic foot ulcers: topical MSI- 78 vs oral ofloxacin. Diabetologia 1997; 40: A482
11. Lipsky BA, Litka PA, et al. Microbial eradication and clinical resolution of infected diabetic foot ulcers treated with topical MSI-78 vs oral ofloxacin. Abstract LM-57. 37th ICAAC, September 1997; Toronto, Canada.
12. Miyasaki KT, Iofel R, Oren A, Huynh T,Lehrer RI. Killing of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia by protegrins. J Periodontal Res, 1998; 33(2): 91-8
13. Matsuzaki K, Sugishita K, Harada M, Fujii N, Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with outer and inner membranes of Gram-negative bacteria. Biochim Biophys Acta, 1997; 1327(1): 119-30
14. Iwahori A, Hirota Y, Sampe R, Miyano S, Numao N. Synthesis of reversed magainin 2 analogs enhanced antibacterial activity. Biol Pharm Bull. 1997; 20(3): 267-70
15. Fuchs PC, Barry AL, Brown SD. In vitro antimicrobial activity of MSI-78, a magainin analog. Antimicrob Agents Chemother. 1998; 42: 1213-6
16. Matsuzaki K, Nakamura A, Murase O, Sugishita K, Fujii N, Miyajima K. Modulation of magainin 2-lipid bilayer interactions by peptide charge. Biochemistry, 1997; 36(8): 2104-11
17. Ge Y, MacDonald D, Henry MM, Hait HI, Naelson KA, Lipsky BA, Zasloff MA, Holroyd KJ. In vitro susceptibility to pexiganan of bacteria isolated from infected diabetic foot ulcers.Diagn Microbiol Infect Dis. 1999; 35(1): 45-53
18. Lamb HM, Wiseman LR. Pexiganan acetate. Drugs, 1998; 56(6):1047-52; 1053-4
19. Numao N, Hirota Y, Iwahori A, Kidokoro S, Sasatsu M, Kondo I, Itoh S, Itoh E et al. Biological activities of 1,1, trisubstituted indanes: beyond magainin 2. Biol Pharm Bull, 1999; 22(1): 73-6